HRP20160608T1 - Novi disupstituirani spojevi 3,4-diamino-3-ciklobuten-1,2-diona, namijenjeni upotrebi u liječenju bolesti posredovanih kemokinima - Google Patents
Novi disupstituirani spojevi 3,4-diamino-3-ciklobuten-1,2-diona, namijenjeni upotrebi u liječenju bolesti posredovanih kemokinima Download PDFInfo
- Publication number
- HRP20160608T1 HRP20160608T1 HRP20160608TT HRP20160608T HRP20160608T1 HR P20160608 T1 HRP20160608 T1 HR P20160608T1 HR P20160608T T HRP20160608T T HR P20160608TT HR P20160608 T HRP20160608 T HR P20160608T HR P20160608 T1 HRP20160608 T1 HR P20160608T1
- Authority
- HR
- Croatia
- Prior art keywords
- radical
- methyl
- atom
- amino
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552940P | 2011-10-28 | 2011-10-28 | |
| FR1159833A FR2981935B1 (fr) | 2011-10-28 | 2011-10-28 | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| PCT/FR2012/052478 WO2013061004A1 (fr) | 2011-10-28 | 2012-10-26 | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines |
| EP12791825.8A EP2771329B1 (fr) | 2011-10-28 | 2012-10-26 | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160608T1 true HRP20160608T1 (hr) | 2016-07-01 |
Family
ID=45809111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160608TT HRP20160608T1 (hr) | 2011-10-28 | 2012-10-26 | Novi disupstituirani spojevi 3,4-diamino-3-ciklobuten-1,2-diona, namijenjeni upotrebi u liječenju bolesti posredovanih kemokinima |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9388149B2 (OSRAM) |
| EP (1) | EP2771329B1 (OSRAM) |
| JP (1) | JP6068486B2 (OSRAM) |
| KR (1) | KR20140090168A (OSRAM) |
| CN (1) | CN103906738B (OSRAM) |
| AU (1) | AU2012328198A1 (OSRAM) |
| BR (1) | BR112014009889A2 (OSRAM) |
| CA (1) | CA2848263A1 (OSRAM) |
| CY (1) | CY1117705T1 (OSRAM) |
| DK (1) | DK2771329T3 (OSRAM) |
| ES (1) | ES2569053T3 (OSRAM) |
| FR (1) | FR2981935B1 (OSRAM) |
| HR (1) | HRP20160608T1 (OSRAM) |
| HU (1) | HUE029128T2 (OSRAM) |
| IN (1) | IN2014CN02273A (OSRAM) |
| MX (1) | MX342924B (OSRAM) |
| PL (1) | PL2771329T3 (OSRAM) |
| PT (1) | PT2771329E (OSRAM) |
| RS (1) | RS54775B1 (OSRAM) |
| RU (1) | RU2014121390A (OSRAM) |
| SI (1) | SI2771329T1 (OSRAM) |
| SM (1) | SMT201600151B (OSRAM) |
| WO (1) | WO2013061004A1 (OSRAM) |
| ZA (1) | ZA201401678B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3076968B1 (en) | 2013-12-02 | 2019-04-17 | ChemoCentryx, Inc. | Ccr6 compounds |
| FR3030515B1 (fr) | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| CN111225900A (zh) | 2017-08-14 | 2020-06-02 | 阿勒根公司 | 3,4-二取代的3-环丁烯-1,2-二酮及其用途 |
| IL275839B2 (en) * | 2018-01-08 | 2024-02-01 | Chemocentryx Inc | Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist |
| WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
| MA53643A (fr) | 2018-09-21 | 2021-12-29 | Pfizer | Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 |
| PH12022500015A1 (en) | 2020-04-30 | 2023-09-11 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| EP4423082A1 (en) | 2021-10-26 | 2024-09-04 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| AR127486A1 (es) | 2021-10-28 | 2024-01-31 | Idorsia Pharmaceuticals Ltd | Moduladores del receptor ccr6 |
| WO2024222865A1 (zh) * | 2023-04-28 | 2024-10-31 | 武汉朗来科技发展有限公司 | 作为ccr6拮抗剂的化合物、其药物组合物和用途 |
| WO2025092968A1 (zh) * | 2023-11-03 | 2025-05-08 | 武汉朗来科技发展有限公司 | 作为ccr6拮抗剂的化合物、其药物组合物和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6652737B2 (en) * | 2000-07-21 | 2003-11-25 | Exxonmobil Research And Engineering Company | Production of naphtha and light olefins |
| KR100952531B1 (ko) * | 2001-04-16 | 2010-04-12 | 쉐링 코포레이션 | Ｃｘｃ-케모카인 수용체 리간드로서의 3,4-이치환된사이클로부텐-1,2-디온 |
| EP2155670B1 (en) * | 2007-06-06 | 2012-04-18 | Novartis AG | Anti -inflammatory substituted cyclobutenedione compounds |
| UA103198C2 (en) * | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| KR200444641Y1 (ko) * | 2008-12-03 | 2009-05-27 | 강민수 | 헤드작동형 다기능 스패너 |
| WO2010063802A1 (en) * | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| WO2010131145A1 (en) * | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
-
2011
- 2011-10-28 FR FR1159833A patent/FR2981935B1/fr not_active Expired - Fee Related
-
2012
- 2012-10-26 RS RS20160367A patent/RS54775B1/sr unknown
- 2012-10-26 CA CA2848263A patent/CA2848263A1/fr not_active Abandoned
- 2012-10-26 WO PCT/FR2012/052478 patent/WO2013061004A1/fr not_active Ceased
- 2012-10-26 CN CN201280052911.8A patent/CN103906738B/zh not_active Expired - Fee Related
- 2012-10-26 BR BR112014009889A patent/BR112014009889A2/pt not_active IP Right Cessation
- 2012-10-26 US US14/354,033 patent/US9388149B2/en not_active Expired - Fee Related
- 2012-10-26 JP JP2014537704A patent/JP6068486B2/ja not_active Expired - Fee Related
- 2012-10-26 HU HUE12791825A patent/HUE029128T2/en unknown
- 2012-10-26 RU RU2014121390/04A patent/RU2014121390A/ru not_active Application Discontinuation
- 2012-10-26 DK DK12791825.8T patent/DK2771329T3/en active
- 2012-10-26 PT PT127918258T patent/PT2771329E/pt unknown
- 2012-10-26 KR KR1020147011443A patent/KR20140090168A/ko not_active Withdrawn
- 2012-10-26 MX MX2014003958A patent/MX342924B/es active IP Right Grant
- 2012-10-26 HR HRP20160608TT patent/HRP20160608T1/hr unknown
- 2012-10-26 IN IN2273CHN2014 patent/IN2014CN02273A/en unknown
- 2012-10-26 ES ES12791825.8T patent/ES2569053T3/es active Active
- 2012-10-26 AU AU2012328198A patent/AU2012328198A1/en not_active Abandoned
- 2012-10-26 SI SI201230577A patent/SI2771329T1/sl unknown
- 2012-10-26 PL PL12791825.8T patent/PL2771329T3/pl unknown
- 2012-10-26 EP EP12791825.8A patent/EP2771329B1/fr active Active
-
2014
- 2014-03-06 ZA ZA2014/01678A patent/ZA201401678B/en unknown
-
2016
- 2016-05-31 SM SM201600151T patent/SMT201600151B/it unknown
- 2016-06-02 CY CY20161100489T patent/CY1117705T1/el unknown
- 2016-06-07 US US15/175,363 patent/US9580412B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK2771329T3 (en) | 2016-06-06 |
| CA2848263A1 (fr) | 2013-05-02 |
| SI2771329T1 (sl) | 2016-07-29 |
| BR112014009889A2 (pt) | 2017-04-25 |
| FR2981935A1 (fr) | 2013-05-03 |
| ZA201401678B (en) | 2015-04-29 |
| CY1117705T1 (el) | 2017-05-17 |
| RS54775B1 (sr) | 2016-10-31 |
| ES2569053T3 (es) | 2016-05-06 |
| CN103906738A (zh) | 2014-07-02 |
| MX2014003958A (es) | 2014-08-27 |
| PT2771329E (pt) | 2016-06-17 |
| PL2771329T3 (pl) | 2016-09-30 |
| CN103906738B (zh) | 2016-09-07 |
| WO2013061004A1 (fr) | 2013-05-02 |
| IN2014CN02273A (OSRAM) | 2015-06-19 |
| US20140296254A1 (en) | 2014-10-02 |
| FR2981935B1 (fr) | 2015-08-07 |
| AU2012328198A1 (en) | 2014-04-03 |
| HUE029128T2 (en) | 2017-02-28 |
| RU2014121390A (ru) | 2015-12-10 |
| EP2771329B1 (fr) | 2016-03-16 |
| US9580412B2 (en) | 2017-02-28 |
| WO2013061004A8 (fr) | 2014-04-17 |
| SMT201600151B (it) | 2016-07-01 |
| KR20140090168A (ko) | 2014-07-16 |
| JP2014530894A (ja) | 2014-11-20 |
| MX342924B (es) | 2016-10-19 |
| US20160362403A1 (en) | 2016-12-15 |
| US9388149B2 (en) | 2016-07-12 |
| EP2771329A1 (fr) | 2014-09-03 |
| JP6068486B2 (ja) | 2017-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160608T1 (hr) | Novi disupstituirani spojevi 3,4-diamino-3-ciklobuten-1,2-diona, namijenjeni upotrebi u liječenju bolesti posredovanih kemokinima | |
| RU2014121394A (ru) | Двузамещенные соединения диамино-3,4-циклобутен-3-диона-1,2, приемлемые для лечения паталогий, опосредованных хемокинами | |
| JP6853619B2 (ja) | シアノトリアゾール化合物の医薬用途 | |
| JP2013509442A5 (OSRAM) | ||
| JP2014505037A5 (OSRAM) | ||
| HRP20171258T1 (hr) | Acilamino-supstituirani kondenzirani derivati ciklopentankarboksilne kiseline i njihova upotreba kao farmaceutski proizvodi | |
| JP2013525433A5 (OSRAM) | ||
| RU2013126041A (ru) | Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2 | |
| JP2013525448A5 (OSRAM) | ||
| JP2010539083A5 (OSRAM) | ||
| JP2016506369A5 (OSRAM) | ||
| RU2013146011A (ru) | Сульфонамидные соединения, обладающие антагонистической активностью в отношении trpm8 | |
| RU2005120018A (ru) | Тиено {3,2-b} пиридин-6-карбонитрилы и тиено {2,3-b} пиридин -5-карбонитрилы в качестве ингибиторов протеинкиназы | |
| JP2015527394A5 (OSRAM) | ||
| RU2015143000A (ru) | N-(4-(азаиндазол-6-ил)-фенил)-сульфонамиды и их применение в качестве лекарственных средств | |
| JP2013501720A5 (OSRAM) | ||
| JP2005509024A5 (OSRAM) | ||
| HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
| JP2013536259A5 (OSRAM) | ||
| ME02675B (me) | Novi derivati cikloheksilamina sa aktivnostima beta2 adrenergijskog agonista i m3 muscarinskog antagonista | |
| JP2006524673A5 (OSRAM) | ||
| HRP20140098T1 (hr) | Derivati piridin-4-ila kao agonisti s1p1/edg1 | |
| JP2017501236A5 (OSRAM) | ||
| JP2016501185A5 (OSRAM) | ||
| RU2016115487A (ru) | Тиазолопиримидиноны в качестве модуляторов активности рецепторов nmda |